Table 2 Adjusted effect of post-remission treatment on cost according to younger and older AML population.
From: Cost comparison of post-remission strategies in younger and older AML patients in France
AML patients ≥18 and ≤60 years old | AML patients >60 years old | ||||
|---|---|---|---|---|---|
Variables | Exp(β) [95 CI] | p | Exp(β) [95 CI] | p | |
Age | 1 [1–1.01] | 0.427 | 1.01 [0.98–1.03] | 0.628 | |
Sex | Women | 1 | 1 | ||
Men | 1.01 [0.91–1.13] | 0.802 | 0.95 [0.74–1.23] | 0.722 | |
Allo-HSCT | 0 | 1 | 1 | ||
1 | 3.28 [2.86–3.77] | <0.001 | 2.00 [1.18–3.38] | 0.010 | |
Favorable | 1 | 1 | |||
Cytogenetic risk | Intermediate | 1.02 [0.85–1.23] | 0.826 | 1.11 [0.82–1.49] | 0.584 |
Adverse | 1.06 [0.98–1.16] | 0.162 | 0.70 [0.46–1.06] | 0.090 | |
Relapse or death during study period | 0 | 1 | 1 | ||
1 | 0.99 [0.79–1.24] | 0.932 | 1.23 [0.59–2.57] | 0.584 | |
Treatment for younger AML | HDAC-135 | 1 | |||
HDAC-123 | 0.84 [0.75–0.94] | 0.002 | |||
Numbers of cycles | 1.57 [1.45–1.7] | <0.001 | |||
Treatment for older AML | IDAC | 1 | |||
SDAC/a | 0.24 [0.18–0.31] | <0.001 | |||
